Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
-
- Giovanni Barosi
- Center for the Study of Myelofibrosis, Biotechnology Research Area, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy;
-
- Ruben Mesa
- Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ;
-
- Guido Finazzi
- Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy;
-
- Claire Harrison
- Department of Haematology, St Thomas Hospital, London, United Kingdom;
-
- Jean-Jacques Kiladjian
- Saint-Louis Hospital and Paris Diderot University, Paris, France;
-
- Eva Lengfelder
- Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany;
-
- Mary F. McMullin
- Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, United Kingdom;
-
- Francesco Passamonti
- Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy;
-
- Alessandro M. Vannucchi
- University of Florence, Florence, Italy;
-
- Carlos Besses
- Department of Hematology, Institut Hospital del Mar d'Investigations Mediques, Barcelona, Spain;
-
- Heinz Gisslinger
- University of Vienna, Department of Internal Medicine, Wien, Austria;
-
- Jan Samuelsson
- Department of Internal Medicine, Karolinska Institute at Stockholm South Hospital, Stockholm, Sweden;
-
- Srdan Verstovsek
- MD Anderson Cancer Center, Houston, TX;
-
- Ronald Hoffman
- Division of Hematology/Oncology, Pathology and Surgery, Tisch Cancer Institute, Myeloproliferative Disorders Research Consortium, Mount Sinai School of Medicine, New York, NY;
-
- Animesh Pardanani
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; and
-
- Francisco Cervantes
- University of Barcelona, Hospital Clínic, Hematology Department, Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
-
- Ayalew Tefferi
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; and
-
- Tiziano Barbui
- Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy;
抄録
<jats:title>Key Points</jats:title><jats:p>Evidence exists that ELN criteria for response in ET and PV issued in 2009 do not provide relevant measures of benefit for patients. Revised recommendations for assessing response are provided.</jats:p>
収録刊行物
-
- Blood
-
Blood 121 (23), 4778-4781, 2013-06-06
American Society of Hematology